Sigma-Aldrich has announced the launch of the Sage Priority Partners programme, which seeks researchers to evaluate new knockout rat models to support pre-clinical research across a number of fields.
Through the Sage Priority Partners Programme, the company plans to build a network of researchers to evaluate the knockout rat models it is developing to support pre-clinical research work across neurobiology, toxicology, cardiology, immunology and others.
The programme, managed by Sigma Advanced Genetic Engineering (Sage) Labs, aims to validate the company's portfolio of genetically-engineered rodent research models, developed using Sigma-Aldrich's Compozr Zinc Finger Nuclease (ZFN) gene-editing technology.
Compzr ZFN enables scientists to knockout specific genes that are associated with human disease.
Partners will be asked to conduct their own evaluation studies and provide feedback, and in return will be offered a number of benefits, including first access to new knockout models and ordering priority and fulfilment, as well as participating in the establishment of the research and development pipeline for this technology.
Initially, Sage Labs will be working on knockout rat models that target more than 20 genes across a number of research areas.
One example is neurobiology, where knockout rat models are being developed with conditions such as schizophrenia, Parkinson's, obesity and Alzheimer's.
